<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146362">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01995786</url>
  </required_header>
  <id_info>
    <org_study_id>19.11</org_study_id>
    <nct_id>NCT01995786</nct_id>
  </id_info>
  <brief_title>Clinical Outcomes and Costs Analyses in Use of Goal Directed Therapy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regina Elena Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regina Elena Cancer Institute</source>
  <oversight_info>
    <authority>Italy: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate clinical and economic impact of Goal Directed Fluid
      Therapy according to NICE haemodynamic protocol. Haemodynamic parameters were assessed using
      automated pulse contour analysis (Flotrac/Vigileo®). A specific dedicated software has been
      developed to perform clinical and expenditures data collection, both retrospective and
      prospective data are archived.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>rate of reduction of postoperative spending</measure>
    <time_frame>30 day postoperative</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Postoperative Complications</condition>
  <arm_group>
    <arm_group_label>Conventional Intravenous Fluid therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Basal infusion of crystalloid (normal saline,Ringer's lactate,Ringer's solution)variable from 4 to 12 ml/kg/hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GDT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Basal infusion of crystalloids (normal saline,Ringer's lactate,Ringer's solution) at 2,5 ml/kg/h and boluses of crystalloids for values of  stroke volume (SV) &lt;  SV TRIGGER.  Every additional infusion of colloids, blood derivates, drugs must be recorded</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Goal Directed Fluid Therapy FloTrac/Vigileo</intervention_name>
    <arm_group_label>GDT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients selected for major abdominal surgery

        Exclusion Criteria:

        •Patients under the age of 18, patients with hemodynamically significant aortic
        regurgitation and heart rhythm disorders
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ester Forastiere</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regina Elena CI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ester Forastiere, M.D.</last_name>
    <email>forastiere@ifo.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regina Elena CI</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 26, 2013</lastchanged_date>
  <firstreceived_date>November 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Regina Elena Cancer Institute</investigator_affiliation>
    <investigator_full_name>Ester Forastiere</investigator_full_name>
    <investigator_title>chief</investigator_title>
  </responsible_party>
  <keyword>Fluid Therapy</keyword>
  <keyword>Cost-Benefit Analysis</keyword>
  <keyword>Hemodynamics</keyword>
  <keyword>Cost Control</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
